Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1/2 1

Status

Suspended 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 7Other hematologic neoplasm 4Lymphoid 4Breast 4Thoracic 2Head & Neck 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Other 1Myeloid 1Gynecologic 1

Conditions

Pneumonia 1Lung Neoplasms 1Lung Diseases, Interstitial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 510Cisplatin 410Pemetrexed 400Radiotherapy 285Docetaxel 244Paclitaxel 227pembrolizumab 226Gemcitabine 198Drug Therapy 191Bevacizumab 190Erlotinib Hydrochloride 189Radiosurgery 177Nivolumab 168Etoposide 155durvalumab 154osimertinib 126atezolizumab 109Gefitinib 96Blood Specimen Collection 93Magnetic Resonance Spectroscopy 91Vinorelbine 90anlotinib 88Surgical Procedures, Operative 85Ipilimumab 62Immunotherapy 62Surveys and Questionnaires 60sintilimab 59Specimen Handling 59tislelizumab 58Irinotecan 57

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Clinical Protocols × Thoracic × Clear all
NCT04210492 2025-05-14

Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer

Yale University

Phase 1/2 Recruiting
36 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04036721 2023-02-23

PROS-CONS

National Institute for Tuberculosis and Lung Diseases, Poland

Phase 4 Suspended
85 enrolled
Thoracic

Lung Neoplasms, Pneumonia, Lung Diseases, Interstitial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡